NorthWest Biotherapeutics Inc (NWBO)

[exwannabe]

Randomized double blind trials with PFS as the main endpoint with OS follow up as 2nd endpoint are the GOLD STANDARD.

The GOLD STANDARD is a randomized trial with OS as the endpoint, And the NWBO -L P3 was not that.

A trial as you describe (and the NWBO designed -L P3) is/was very common, especially as a P2 with a hope for accelerated approval, It gives a chance for faster results while also a chance to prove OS.

OTOH, NWBO ran such a trial. But after finding out the trial as designed failed, they compared OS to summery data from other trials. Anybody with a clue in this space knows that is a JOKE.